GlassScriptPhysician profile
David Oligschlaeger
NPI 1851383418
$9,695.70
in general payments reported to CMS, 2019-2025
43 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,331 · 2020: $1,184 · 2021: $1,663 · 2022: $1,319 · 2023: $1,456 · 2024: $1,450 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,159 · Education: $39.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,159.11 |
| Education | $39.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,200.51 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,100.11 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $906.58 | 2019-2025 | |
| Abbvie INC. | $854.81 | 2021-2025 | |
| Amgen INC. | $767.04 | 2019-2024 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $548.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $518.27 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $470.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $469.01 | 2019-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $329.68 | 2019-2022 | |
| Abbott Laboratories | $295.61 | 2019-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $253.46 | 2023-2025 | Rexulti |
| Preventric Diagnostics, INC. | $221.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $195.27 | 2020-2025 | Eliquis |
| Sumitomo Pharma America, INC. | $175.87 | 2023-2024 | Aptiom, Gemtesa |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oligschlaeger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.